Division of Mayne Pharma Group Ltd.
Latest From Metrics Inc.
In a deal valued at $272 million, AZ got exclusive global rights to Ardelyx’s NHE3 program. Pfizer exercised an option to buy spec pharma NextWave for $255 million up front. Biophama companies raised almost $2 billion in October propelled by public offerings. Early venture rounds dominated device financing, which totaled $193 million.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Contract Research, Toxicology Testing-CRO
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Mayne Pharma Group Ltd.
- Senior Management
Steve Taylor, CFO & VP, Fin. & Human Resources
Jeffery C Basham, VP, Bus. Dev.
William P Hodges, Pres.
Michael D Ruff, VP, Pharma Dev.
- Contact Info
Phone: (252) 752-3800
1240 Sugg Pkwy.
Greenvile, NC 27834
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.